Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 11/20 | 0.45 |
| ▸ | HRH1 | P35367 | 11/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22325298 | 1.00 | TLR8 (0.45) | TLR8HRH2HRH1EPHX2ACKR3 | |
| SCHEMBL21069069 | 0.99 | TLR8 (0.46) | TLR8HRH2HRH1EPHX2ACKR3 | |
| SCHEMBL6421573 | 0.95 | TLR8 (0.47) | TLR8HRH2HRH1ACKR3 | |
| SCHEMBL4360530 | 0.89 | KMT2A (0.46) | TLR8 | |
| SCHEMBL22325407 | 0.86 | EPHX2 (0.45) | TLR8EPHX2ACKR3PAOX | |
| SCHEMBL22325269 | 0.86 | EPHX2 (0.45) | TLR8EPHX2ACKR3PAOX | |
| SCHEMBL29290835 | 0.86 | EPHX2 (0.45) | TLR8EPHX2ACKR3PAOX | |
| SCHEMBL8253901 | 0.86 | USP2 (0.51) | TLR8EPHX2ACKR3 | |
| SCHEMBL25247792 | 0.86 | TLR8 (0.42) | TLR8HRH2HRH1ACKR3 | |
| SCHEMBL31465617 | 0.85 | EPHX2 (0.46) | TLR8EPHX2ACKR3PAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7700306-B2 | characterising a polypeptide by matrix assisted laser desorption ionization (MALDI) mass spectrometry; improving sensitivity, and can increase the number of peptides that are detected from a protein | ELECTROPHORETICS LIMITED (GB) | 2010-04-20 | — | — | US | disclosed |
| US-7700306-B2 | characterising a polypeptide by matrix assisted laser desorption ionization (MALDI) mass spectrometry; improving sensitivity, and can increase the number of peptides that are detected from a protein | ELECTROPHORETICS LIMITED (GB) | 2010-04-20 | — | — | US | disclosed |
| US-7700306-B2 | characterising a polypeptide by matrix assisted laser desorption ionization (MALDI) mass spectrometry; improving sensitivity, and can increase the number of peptides that are detected from a protein | ELECTROPHORETICS LIMITED (GB) | 2010-04-20 | — | — | US | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20060040334-A1 | Method for characterising analytes | XZILLION GMBH & CO. KG (DE) | 2006-02-23 | — | — | US | disclosed |
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1490693-A1 | METHOD FOR CHARACTERISING ANALYTES | Xzillion GmbH & CO.KG (DE) | 2004-12-29 | — | — | EP | disclosed |
| EP-1481966-A1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003087839-A1 | METHOD FOR CHARACTERISING ANALYTES | XZILLION GMBH & CO. KG (DE) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | SLC7A1, NAT1, NACA | TLR8 256/4885HRH2 284/4885HRH1 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.